Table 2.
Baseline characteristics of KTRs explored according to the immunosuppressive regimen
| Baseline Characteristics | Group 1: Tacrolimus-Based IS Regimen, n=24 | P Valuea | Group 2: Belatacept-Based IS Regimen, n=10 | P Valueb | Group 3: Nontacrolimus- and Nonbelatacept-Based IS Regimen, n=11 | P Valuec |
|---|---|---|---|---|---|---|
| Age, yr | 60.2±17.4 | 0.21 | 68.1±13.7 | 0.82 | 66.6±15.5 | 0.29 |
| Sex (M/W), n | 12/12 | 0.59 | 6/4 | 0.51 | 5/6 | |
| Time from transplantation, yr | 6.1±4.9 | 0.92 | 6.3±4.7 | 0.001 | 17.1±7.9 | <0.001 |
| eGFR, ml/min per 1.73 m2 | 45.6±13.7 | 0.005 | 30.4±11.6 | 0.007 | 50.1±17.4 | 0.41 |
| Induction therapy for KT, n (%) | ||||||
| ATG | 11 (45.8) | 0.16 | 2 (20) | 0.21 | 5 (45.5) | |
| Anti–R-IL2 | 13 (54.2) | 8 (80) | 6 (54.5) | |||
| IS regimen, n (%) | ||||||
| Tacrolimus | 24 (100) | <0.001 | 0 | <0.001 | 0 | <0.001 |
| C0 tacrolimus | 6.1±1.8 | 0.007 | — | 0.54 | — | <0.001 |
| Cyclosporin | 0 | 0.78 | 0 | 0.69 | 8 (72.7) | 0.05 |
| C0 cyclosporin | — | 0.14 | — | 0.48 | 67.2±15.3 | 0.26 |
| MMF | 23 (95.8) | 0.12 | 6 (60) | 0.60 | 8 (72.7) | 0.56 |
| MMF median of dosage, mg | 1000 | <0.01 | 625 | <0.001 | 1000 | 0.03 |
| AZA | 1 (4.2) | 0.13 | 2 (20) | 0.12 | 1 (9.1) | 0.77 |
| Everolimus | 0 | 1 10) | 2 (18.2) | |||
| Belatacept | 0 | 10 (100) | 0 | |||
| Steroids | 10 (41.7) | 7 (70) | 4 (36.4) |
IS, immunosuppressive; M, men; W, women; KT, kidney transplantation; ATG, antithymoglobuline; R-IL2, IL-2 receptor; C0, through level; MMF, mycophenolate mofetil; AZA, azathioprine.
a
Comparison between groups 1 and 2.
b
Comparison between groups 2 and 3.
c
Comparison between groups 1 and 3.